Damora Therapeutics (DMRA)
NASDAQ:DMRA
Total Valuation
Damora Therapeutics has a market cap or net worth of $1.47B. The enterprise value is $1.21B.
Market Cap$1.47B
Enterprise Value$1.21B
Share Statistics
Damora Therapeutics has 60,303,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,303,210
Owned by Insiders15.51%
Owned by Institutions0.90%
Financial Efficiency
Damora Therapeutics’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -87.69%.
Return on Equity (ROE)-0.87
Return on Assets (ROA)-0.81
Return on Invested Capital (ROIC)-87.69%
Return on Capital Employed (ROCE)-0.88
Revenue Per Employee0.00
Profits Per Employee-29.98M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Damora Therapeutics is ―. Damora Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF0.00
Price to Operating Cash Flow57.07
PEG Ratio0.00
Income Statement
In the last 12 months, Damora Therapeutics had revenue of 0.00 and earned -209.84M in profits. Earnings per share was -158.13.
Revenue0.00
Gross Profit0.00
Operating Income-210.87M
Pretax Income-209.79M
Net Income-209.84M
EBITDA-210.84M
Earnings Per Share (EPS)-158.13
Cash Flow
In the last 12 months, operating cash flow was 566.00K and capital expenditures 0.00, giving a free cash flow of 566.00K billion.
Operating Cash Flow566.00K
Free Cash Flow566.00K
Free Cash Flow per Share<0.01
Dividends & Yields
Damora Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change989.29%
50-Day Moving Average26.22
200-Day Moving Average14.99
Relative Strength Index (RSI)47.77
Average Volume (3m)5.26M
Important Dates
Damora Therapeutics upcoming earnings date is Apr 24, 2026, Before Open (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateApr 24, 2026
Ex-Dividend Date―
Financial Position
Damora Therapeutics as a current ratio of 12.98, with Debt / Equity ratio of 0.03%
Current Ratio12.98
Quick Ratio12.98
Debt to Market Cap0.00
Net Debt to EBITDA1.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Damora Therapeutics has paid 50.00K in taxes.
Income Tax50.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Damora Therapeutics EV to EBITDA ratio is 1.22, with an EV/FCF ratio of 38.29.
EV to Sales0.00
EV to EBITDA1.22
EV to Free Cash Flow38.29
EV to Operating Cash Flow38.29
Balance Sheet
Damora Therapeutics has $257.62M in cash and marketable securities with $68.00K in debt, giving a net cash position of $257.56M billion.
Cash & Marketable Securities$257.62M
Total Debt$68.00K
Net Cash$257.56M
Net Cash Per Share$4.27
Tangible Book Value Per Share$0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Damora Therapeutics is $44.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$44.00
Price Target Upside80.33% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast37.42%